作者
Giorgio Walter Canonica, Giorgio Lorenzo Colombo, Giacomo Matteo Bruno, Sergio Di Matteo, Chiara Martinotti, Francesco Blasi, Caterina Bucca, Nunzio Crimi, Pierluigi Paggiaro, Girolamo Pelaia, Giovanni Passalaqua, Gianenrico Senna, Enrico Heffler, Stefano Aliberti, Diego Bagnasco, Sarah Barbuto, Gianna Camiciottoli, Marco Caminati, Giselda Colombo, Teresa Costantino Maria, Claudia Crimi, Mariangiola Crivellaro, Mariella D'Amato, Elisabetta Favero, Pia Foschino Maria, Gabriella Guarnieri, Manuela Latorre, Carlo Lombardi, Francesco Menzella, Vincenzo Patella, Francesca Puggioni, Erminia Ridolo, Giovanni Rolla, Eleonora Savi, Nicola Scichilone, Paolo Solidoro, Giuseppe Spadaro, Massimo Triggiani
发表日期
2019/1/1
期刊
World Allergy Organization Journal
卷号
12
期号
1
页码范围
100007
出版商
Elsevier
简介
Background
Asthma is one of the most common non-communicable respiratory diseases, affecting about 6% of the general population. Severe asthma, even if afflicts a minority of asthmatics, drives the majority of costs of the disease. The aim of this study is to create a pharmacoeconomic model to predict the costs of corticosteroid-related adverse events in severe asthmatics and applying it to the first published epidemiologic data from the Severe Asthma Network in Italy (SANI) registry.
Methods
The analysis was conducted from the perspective of the Italian National Healthcare System (INHS). Model inputs, derived from literature, included: asthma epidemiology data, frequency of adverse events, percentage of severe asthma treated with OCS and adverse event cost (Diagnosis-Related Group (DRG) national tariffs). We estimated costs per different patient groups: non-asthma controls, mild/moderate and severe …
学术搜索中的文章
GW Canonica, GL Colombo, GM Bruno, S Di Matteo… - World Allergy Organization Journal, 2019